United Therapeutics Corporation is a drug manufacturers - specialty & generic business based in the US. United Therapeutics Corporation shares (UTHR) are listed on the NASDAQ and all prices are listed in US Dollars. United Therapeutics Corporation employs 1,305 staff and has a trailing 12-month revenue of around $3.1 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
United Therapeutics Corporation stock price (NASDAQ: UTHR)
Use our graph to track the performance of UTHR stocks over time.
United Therapeutics Corporation shares at a glance
Is it a good time to buy United Therapeutics Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is United Therapeutics Corporation stock undervalued or overvalued?
Valuing United Therapeutics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of United Therapeutics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
United Therapeutics Corporation's P/E ratio
United Therapeutics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, United Therapeutics Corporation shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
United Therapeutics Corporation's PEG ratio
United Therapeutics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4347. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into United Therapeutics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
United Therapeutics Corporation's EBITDA
United Therapeutics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 billion.
The EBITDA is a measure of a United Therapeutics Corporation's overall financial performance and is widely used to measure a its profitability.
United Therapeutics Corporation financials
Revenue TTM
$3.1 billion
Operating margin TTM
48.69%
Gross profit TTM
$2.8 billion
Return on assets TTM
13.14%
Return on equity TTM
20.04%
Profit margin
40.65%
Book value
$153.61
Market Capitalization
$22.1 billion
TTM: trailing 12 months
United Therapeutics Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like United Therapeutics Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
United Therapeutics Corporation's total ESG risk score
Total ESG risk: 35.51
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and United Therapeutics Corporation's overall score of 35.51 (as at 12/31/2018) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like United Therapeutics Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
United Therapeutics Corporation's environmental score
Environmental score: 6.16/100
United Therapeutics Corporation's environmental score of 6.16 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
United Therapeutics Corporation's social score
Social score: 24.94/100
United Therapeutics Corporation's social score of 24.94 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
United Therapeutics Corporation's governance score
Governance score: 17.41/100
United Therapeutics Corporation's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that United Therapeutics Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
United Therapeutics Corporation's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. United Therapeutics Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that United Therapeutics Corporation has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
United Therapeutics Corporation was last rated for ESG on: 2019-01-01.
Total ESG score
35.51
Total ESG percentile
53.55
Environmental score
6.16
Environmental score percentile
9
Social score
24.94
Social score percentile
9
Governance score
17.41
Governance score percentile
9
Level of controversy
2
United Therapeutics Corporation share dividends
We're not expecting United Therapeutics Corporation to pay a dividend over the next 12 months.
Have United Therapeutics Corporation's shares ever split?
United Therapeutics Corporation's shares were
split on a 2:1 basis on 22 September 2009
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your United Therapeutics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for United Therapeutics Corporation shares which in turn could have impacted United Therapeutics Corporation's share price.
United Therapeutics Corporation share price volatility
Over the last 12 months, United Therapeutics Corporation's shares have ranged in value from as little as $266.98 up to $492.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United Therapeutics Corporation's is 0.868. This would suggest that United Therapeutics Corporation's shares are less volatile than average (for this exchange).
United Therapeutics Corporation overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
Frequently asked questions
What percentage of United Therapeutics Corporation is owned by insiders or institutions? Currently 1.853% of United Therapeutics Corporation shares are held by insiders and 98.786% by institutions.How many people work for United Therapeutics Corporation? Latest data suggests 1,305 work at United Therapeutics Corporation.When does the fiscal year end for United Therapeutics Corporation? United Therapeutics Corporation's fiscal year ends in December.Where is United Therapeutics Corporation based? United Therapeutics Corporation's address is: 1000 Spring Street, Silver Spring, MD, United States, 20910What is United Therapeutics Corporation's ISIN number? United Therapeutics Corporation's international securities identification number is: US91307C1027What is United Therapeutics Corporation's CUSIP number? United Therapeutics Corporation's Committee on Uniform Securities Identification Procedures number is: 91307C102
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
